MENU
BDMD
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

BDMD stock forecast, quote, news & analysis

Baird Medical Investment Holdings Ltd is a specialized healthcare innovator dedicated exclusively to thyroid-related diseases and a microwave ablation (MWA) medical device manufacturer and provider in China... Show more

Interact to see
Advertisement
A.I.Advisor
published price charts
A.I.Advisor
Nov 03, 2026

Why Baird Medical (BDMD) Stock Is Down -81.6% in the Last 30 Days

Key Takeaways

  • Baird Medical (BDMD) shares fell roughly 81.6% over the trailing 30 days, from about $0.75 to $0.14, extending a broader multi-month downtrend.
  • The decline was driven by dilution risk from a $50 million shelf registration and a priced offering, a Weiss Ratings downgrade to "Sell," and heavy sell-side volume in a thinly traded micro-cap.
  • Shares have traded well below $1.00, a level that raises Nasdaq minimum bid price listing compliance considerations for the company.
  • H1 2026 results showed revenue up 24.6% to about $9.9 million and a return to marginal profitability, but full-year 2025 revenue fell 39.2%.
  • Liquidity remains a core risk, with cash and restricted cash of approximately $0.23 million reported as of June 30, 2026.
  • For deeper analysis of this stock, explore its Price Targets, Earnings, and Forecast pages.
  • Explore Trending AI Robots to see how algorithmic trading tools are currently positioning across the market.

Baird Medical (BDMD) Company Overview and Market Position

Baird Medical Investment Holdings Ltd. is a Guangzhou, China-based medical device company founded in 2012. The company designs, develops, manufactures, and sells minimally invasive microwave ablation (MWA) systems and needles used to treat benign and malignant tumors, including thyroid nodules, liver cancer, lung cancer, breast lumps, and uterine fibroids. Its lead product is a microwave ablation system that received U.S. FDA 510(k) clearance for soft tissue ablation and is being launched in the United States primarily for the treatment of benign thyroid nodules. Baird Medical was the first company to obtain a Class III medical device registration in China for MWA devices specifically indicated for thyroid nodules, and it is also developing IRE-based products and an AI-powered robotic ablation system. The company listed on Nasdaq in October 2024 through a business combination with ExcelFin Acquisition Corp., and investors follow the stock for its U.S. commercialization progress and expanding pipeline.

Baird Medical (BDMD) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, BDMD declined from a close of about $0.75 to roughly $0.14, a drop of approximately 81.6%. The decline was not linear: the stock traded near $0.75 in early October before sharp, high-volume selloffs in late October accelerated the move toward $0.14.

The quarterly picture is similarly negative. From about $1.22 in early August, shares fell to roughly $0.14 by early November, a decline of nearly 89%. This reflects a sustained downward trend rather than a single isolated event, with selling pressure intensifying after a registered offering and a ratings downgrade.

What Drove BDMD Stock Price in the Last 30 Days

Several verified factors contributed to the sharp decline. On September 24, 2026, the company priced an offering under its shelf registration, raising dilution concerns in an already thinly traded security. The company had earlier filed a $50 million shelf registration statement on August 6, 2026. On October 6, 2026, Weiss Ratings issued a downgrade on Baird Medical with a "Sell" rating, adding to negative sentiment.

The selloff pushed the stock below $1.00, a threshold that raises Nasdaq minimum bid price listing compliance considerations. Trading volume expanded dramatically in late October and early November, reflecting heavy selling pressure in a low-priced, low-float micro-cap. Broader weakness among Chinese concept stocks during October also weighed on the shares, compounding company-specific concerns around liquidity and the pace at which regulatory approvals are converting into commercial sales.

What Drove BDMD Stock Performance Over the Last Quarter

The multi-month downtrend reflects a broader narrative around a China-based micro-cap navigating a transition toward U.S. commercialization. In August 2026, the company's shelf registration and prospectus updates highlighted a resale overhang and ongoing China-related and Holding Foreign Companies Accountable Act (HFCAA) risks. In September, preliminary H1 2026 results showed revenue up 24.6% year over year and a swing to a narrow net profit, but the figures were preliminary and unaudited, and full-year 2025 revenue had fallen 39.2% due to a policy-related slowdown in mainland China. The combination of modest profitability, a low cash balance, dilution risk, and a sub-$1.00 share price kept sentiment under pressure throughout the quarter.

Trending AI Robots

Tickeron's Trending AI Robots page showcases a curated selection of algorithmic trading bots drawn from hundreds of AI-driven strategies that monitor thousands of tickers. Rather than listing every available bot, the section highlights top-performing and currently relevant robots so traders can quickly identify strategies gaining traction in real time. Each bot differs in its trading approach, timeframe, and performance metrics, which allows users to compare candidates based on their own objectives and risk tolerance. For those interested in complementing manual research with data-driven signals, browsing the Trending AI Robots section can offer a useful starting point for discovering how automated strategies are positioning in current market conditions.

BDMD Stock Forecast Drivers: What Investors Should Watch Next

Going forward, investors are likely to focus on whether Baird Medical's FDA-cleared microwave ablation system converts into sustained U.S. sales, and whether international regulatory approvals in markets such as Vietnam and Egypt translate into reported revenue. Audited interim financial results, any further capital-raising activity under the shelf registration, and the company's cash position will also be closely monitored. Listing compliance remains a key watch item while shares trade below $1.00, as does any update on auditor-related HFCAA risks. Developments in mainland China healthcare policy, which contributed to the 2025 revenue decline, and the broader sentiment toward Chinese concept stocks may continue to influence price action. These are informational considerations only and not investment recommendations.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

A.I.Advisor
a Summary for BDMD with price predictions
Nov 20, 2026

BDMD in upward trend: price may jump up because it broke its lower Bollinger Band on October 19, 2026

BDMD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 25 of 31 cases where BDMD's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 81%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BDMD's RSI Indicator exited the oversold zone, 19 of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.

The Momentum Indicator moved above the 0 level on November 20, 2026. You may want to consider a long position or call options on BDMD as a result. In 32 of 72 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 44%.

The Moving Average Convergence Divergence (MACD) for BDMD just turned positive on November 11, 2026. Looking at past instances where BDMD's MACD turned positive, the stock continued to rise in 20 of 46 cases over the following month. The odds of a continued upward trend are 43%.

Following a +10.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where BDMD advanced for three days, in 70 of 120 cases, the price rose further within the following month. The odds of a continued upward trend are 58%.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BDMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.

The Aroon Indicator for BDMD entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.081) is normal, around the industry mean (4.142). P/E Ratio (-0.159) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (1.371) is also within normal values, averaging (40.124).

The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. BDMD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BDMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -11%. For the same Industry, the average monthly price growth was -15%, and the average quarterly price growth was -18%. MXCT experienced the highest price growth at 15%, while CODX experienced the biggest fall at -50%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -36%. For the same stocks of the Industry, the average monthly volume growth was -3% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 49
Price Growth Rating: 64
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 16 (-100 ... +100)
Why Baird Medical (BDMD) Stock Is Down -81.6% in the Last 30 Days